In a breakthrough that could reshape the future of cannabinoid production, researchers have unraveled the inner workings of two extraordinary enzymes harvested from the ocean’s microbial depths. These marine bacterial flavoenzymes, designated Clz9 and Tcz9, possess the rare ability to transform cannabigerolic acid (CBGA), the central precursor in cannabinoid biosynthesis, into cannabichromenic acid (CBCA), a minor cannabinoid with emerging therapeutic promise. The discovery not only illuminates a completely foreign biochemical route to cannabinoids—divorced from the plant machinery of Cannabis sativa—but also hands bioengineers a powerful toolkit for crafting specific chiral forms of CBCA with unprecedented precision.
For years, the enzymatic landscape of cannabinoid cyclization was dominated by plant-based catalysts, which orchestrate the folding of CBGA into familiar compounds like THCA and CBDA. The marine enzymes Clz9 and Tcz9 shatter that monopoly. Detailed in a new Nature Chemical Biology study, high-resolution crystallographic snapshots captured these proteins in the act, clinging to their substrate. The structures reveal that despite belonging to the same BBE-like enzyme family, Clz9 and Tcz9 sculpt the same chemical product using starkly different active-site architectures, rewriting assumptions about how nature builds molecular complexity.
The team, led by Love, Sirohi, and Hubert, deployed a multi-pronged interrogation combining X-ray crystallography, biochemical kinetics, and spectroscopic probes to dissect every step of the CBCA-forming reaction. A crowning achievement was the capture of a substrate-bound structure at high resolution, freezing the delicate moment when CBGA nestles into the enzyme’s catalytic pocket. This molecular portrait exposed the precise network of amino acid residues and a flavin cofactor that steer the cyclization. Critically, it showed how subtle geometric constraints in the active site dictate which way the precursor molecule twists, ultimately controlling the spatial orientation of the final product.
That stereochemical control is the crux of the breakthrough. Cannabichromenic acid exists as two mirror-image forms—(R)-CBCA and (S)-CBCA—much like left and right hands. Biological systems often distinguish ruthlessly between such enantiomers, and their therapeutic effects can diverge dramatically. The plant’s own machinery typically produces a mixture heavily skewed toward one form, making it difficult to isolate the other. Clz9 and Tcz9, however, naturally exhibit distinct stereoselectivity profiles. By studying the structural blueprints, the researchers identified the precise molecular dials that govern which chiral form emerges from the reaction.
Armed with these insights, the team moved from observation to intervention, engineering mutations into the enzymes that markedly improved their stereoselectivity. The result is a pair of biocatalysts fine-tuned to deliver either (R)-CBCA or (S)-CBCA with high fidelity. This is more than an academic exercise; it is a manufacturing revolution. Current chemical synthesis pathways struggle to produce enantiopure cannabinoids without arduous separation steps. Engineered Clz9 and Tcz9 promise a green, one-pot route from CBGA to chiral CBCA, operating under mild aqueous conditions that are the hallmark of enzymatic transformations.
Beyond the immediate practical payoff, the study delivers a fundamental lesson in enzymatic evolution. The two marine enzymes perform the same chemical task but do so through distinct mechanistic choreography, neither of which mirrors the cyclization cascade used by the plant’s THCA or CBDA synthases. Biochemical analysis revealed divergent reliance on flavin chemistry and proton transfer steps, underscoring that even within the BBE-like superfamily, nature has independently invented multiple catalytic solutions to the same problem. This mechanistic pluralism provides a rich palette for protein engineers seeking to design entirely new-to-nature cyclization reactions.
The implications ripple across the pharmaceutical and nutraceutical sectors. CBCA and its decarboxylated form, cannabichromene (CBC), have been implicated in modulating pain, inflammation, and neurogenesis, though research has been hamstrung by limited access to pure compounds. Having a scalable enzymatic platform that yields specific enantiomers on demand could unlock rigorous clinical studies that were previously impractical. Moreover, the work cements Clz9 and Tcz9 as flagship members of a growing arsenal of biocatalysts for cannabinoid production, complementing yeast-based synthesis platforms that already churn out major cannabinoids via heterologous pathways.
What makes this story particularly viral is the source. The ocean, a reservoir of biochemical dark matter, has now yielded enzymes that can outperform plant catalysts in a synthetic arena directly relevant to human health. The study serves as a reminder that the next blockbuster pharmaceutical ingredient might not come from a tropical rainforest plant but from the genome of a marine microbe blissfully unaware of the botanical drama unfolding on land. By fusing structural biology with synthetic ambition, the researchers have turned a curious marine trick into a tunable molecular factory, opening a new chapter in the quest to produce any cannabinoid, in any form, from any vat.In a breakthrough that could reshape the future of cannabinoid production, researchers have unraveled the inner workings of two extraordinary enzymes harvested from the ocean’s microbial depths. These marine bacterial flavoenzymes, designated Clz9 and Tcz9, possess the rare ability to transform cannabigerolic acid (CBGA), the central precursor in cannabinoid biosynthesis, into cannabichromenic acid (CBCA), a minor cannabinoid with emerging therapeutic promise. The discovery not only illuminates a completely foreign biochemical route to cannabinoids—divorced from the plant machinery of Cannabis sativa—but also hands bioengineers a powerful toolkit for crafting specific chiral forms of CBCA with unprecedented precision.
For years, the enzymatic landscape of cannabinoid cyclization was dominated by plant-based catalysts, which orchestrate the folding of CBGA into familiar compounds like THCA and CBDA. The marine enzymes Clz9 and Tcz9 shatter that monopoly. Detailed in a new Nature Chemical Biology study, high-resolution crystallographic snapshots captured these proteins in the act, clinging to their substrate. The structures reveal that despite belonging to the same BBE-like enzyme family, Clz9 and Tcz9 sculpt the same chemical product using starkly different active-site architectures, rewriting assumptions about how nature builds molecular complexity.
The team, led by Love, Sirohi, and Hubert, deployed a multi-pronged interrogation combining X-ray crystallography, biochemical kinetics, and spectroscopic probes to dissect every step of the CBCA-forming reaction. A crowning achievement was the capture of a substrate-bound structure at high resolution, freezing the delicate moment when CBGA nestles into the enzyme’s catalytic pocket. This molecular portrait exposed the precise network of amino acid residues and a flavin cofactor that steer the cyclization. Critically, it showed how subtle geometric constraints in the active site dictate which way the precursor molecule twists, ultimately controlling the spatial orientation of the final product.
That stereochemical control is the crux of the breakthrough. Cannabichromenic acid exists as two mirror-image forms—(R)-CBCA and (S)-CBCA—much like left and right hands. Biological systems often distinguish ruthlessly between such enantiomers, and their therapeutic effects can diverge dramatically. The plant’s own machinery typically produces a mixture heavily skewed toward one form, making it difficult to isolate the other. Clz9 and Tcz9, however, naturally exhibit distinct stereoselectivity profiles. By studying the structural blueprints, the researchers identified the precise molecular dials that govern which chiral form emerges from the reaction.
Armed with these insights, the team moved from observation to intervention, engineering mutations into the enzymes that markedly improved their stereoselectivity. The result is a pair of biocatalysts fine-tuned to deliver either (R)-CBCA or (S)-CBCA with high fidelity. This is more than an academic exercise; it is a manufacturing revolution. Current chemical synthesis pathways struggle to produce enantiopure cannabinoids without arduous separation steps. Engineered Clz9 and Tcz9 promise a green, one-pot route from CBGA to chiral CBCA, operating under mild aqueous conditions that are the hallmark of enzymatic transformations.
Beyond the immediate practical payoff, the study delivers a fundamental lesson in enzymatic evolution. The two marine enzymes perform the same chemical task but do so through distinct mechanistic choreography, neither of which mirrors the cyclization cascade used by the plant’s THCA or CBDA synthases. Biochemical analysis revealed divergent reliance on flavin chemistry and proton transfer steps, underscoring that even within the BBE-like superfamily, nature has independently invented multiple catalytic solutions to the same problem. This mechanistic pluralism provides a rich palette for protein engineers seeking to design entirely new-to-nature cyclization reactions.
The implications ripple across the pharmaceutical and nutraceutical sectors. CBCA and its decarboxylated form, cannabichromene (CBC), have been implicated in modulating pain, inflammation, and neurogenesis, though research has been hamstrung by limited access to pure compounds. Having a scalable enzymatic platform that yields specific enantiomers on demand could unlock rigorous clinical studies that were previously impractical. Moreover, the work cements Clz9 and Tcz9 as flagship members of a growing arsenal of biocatalysts for cannabinoid production, complementing yeast-based synthesis platforms that already churn out major cannabinoids via heterologous pathways.
What makes this story particularly viral is the source. The ocean, a reservoir of biochemical dark matter, has now yielded enzymes that can outperform plant catalysts in a synthetic arena directly relevant to human health. The study serves as a reminder that the next blockbuster pharmaceutical ingredient might not come from a tropical rainforest plant but from the genome of a marine microbe blissfully unaware of the botanical drama unfolding on land. By fusing structural biology with synthetic ambition, the researchers have turned a curious marine trick into a tunable molecular factory, opening a new chapter in the quest to produce any cannabinoid, in any form, from any vat.
Subject of Research: Structural and biochemical basis for cannabinoid cyclase activity in marine bacterial flavoenzymes
Article Title: Structural and biochemical basis for cannabinoid cyclase activity in marine bacterial flavoenzymes
Article References: Love, A.C., Sirohi, H., Hubert, F.M. et al. Structural and biochemical basis for cannabinoid cyclase activity in marine bacterial flavoenzymes. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02257-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41589-026-02257-3
Keywords: cannabinoid cyclase, marine flavoenzymes, CBCA biosynthesis, stereoselectivity engineering, BBE-like enzymes, biocatalysis, X-ray crystallography, enzyme mechanism, cannabichromenic acid, Cannabigerolic acid
